AbbVie’s Gonzalez Expects More PBM Deals To Come In HCV
This article was originally published in The Pink Sheet Daily
Executive Summary
The AbbVie CEO said his company and Gilead are just engaging in the normal market dynamics that occur when an entrenched product faces viable competition for the first time. Gilead’s formulary agreement for its HCV drugs with CVS quickly followed the rapid decision by Express Scripts to give preferred formulary status to AbbVie’s Viekira Pak.
You may also be interested in...
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Industry & Regulators To Align Advice on COVID-19 Vaccine Updates
A multi-stakeholder workshop looked at the data needed to support updates to vaccine composition and the time required by manufacturers to update their vaccines, change their manufacturing processes and prepare approval applications.